Age Related Vision Dysfunction Market is set to Grow at a Remarkable Pace by 2033
A recently published study by FMI expects the global age related vision dysfunction market to augment at a 3.7% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 130 Billion is expected for the market. The rising incidence of visual impairment and blindness is a primary driver of the global age related vision dysfunction market's expansion.
Furthermore, the rising prevalence of eye illnesses such as
diabetic, glaucoma, cataract, and age-related macular degeneration is expected
to boost demand for assistive technology in age related vision dysfunction. As a
result, the worldwide age
related vision dysfunction market will expand. For example, the
World Glaucoma Association estimates that 79.6 million people would develop
glaucoma by 2020. This figure is expected to rise to 111.8 million by 2040.
According to a United Nations (UN) estimate, the worldwide
population of people aged 60 and more was around 962 million in 2017, with a
projected increase to 2.1 billion by 2050 According to the National Federation
of the Blind, an estimated 3,171,100 persons aged 65 and older in the United
States had visual impairment in 2016. All these factors are likely to drive the
age related vision dysfunction
market during the forecast period.
Market Competition
- Aerie
Pharmaceuticals
- Santen
Pharmaceutical
- Sun
Pharma Advanced Research Company Limited
- Bausch
+ Lomb
- D
Western Therapeutics Institute
- Novartis
- AbbVie
- Eyenovia
- Orasis
Pharmaceuticals
- IVERIC
Bio
Browse
More@ https://www.futuremarketinsights.com/reports/age-related-vision-dysfunction-market
Key
Segments Profiled in the Age Related Vision Dysfunction Market Industry Survey
Age
Related Vision Dysfunction Market by Dysfunction Type:
- Cataract
- AMD
- Glaucoma
- Presbyopia
Age-Related
Vision Dysfunction Market by Drug:
- Rocklatan
- Eybelis
Ophthalmic Solution
- Xelpros
- Rhopressa
- Vyzulta
- Glanatec
- Simbrinza
- Tapcom/DE-111
- Azarga/Azorga
- Combigan
- Lucentis
- Eylea
- Beovu
Comments
Post a Comment